Who are Lotilaner ophthalmic solution, 0.25%'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lotilaner-ophthalmic-solution-0-25.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lotilaner ophthalmic solution, 0.25% — Competitive Intelligence Brief

Lotilaner ophthalmic solution, 0.25% (Lotilaner ophthalmic solution, 0.25%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sigma receptor antagonist. Area: Ophthalmology.

marketed Sigma receptor antagonist Sigma receptors (non-selective) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Lotilaner ophthalmic solution, 0.25% (Lotilaner ophthalmic solution, 0.25%) — Tarsus Pharmaceuticals, Inc.. Lotilaner is a non-selective sigma receptor antagonist that reduces ocular surface inflammation and irritation associated with Demodex mites.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lotilaner ophthalmic solution, 0.25% TARGET	Lotilaner ophthalmic solution, 0.25%	Tarsus Pharmaceuticals, Inc.	marketed	Sigma receptor antagonist	Sigma receptors (non-selective)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sigma receptor antagonist class)

Tarsus Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lotilaner ophthalmic solution, 0.25% — Competitive Intelligence Brief. https://druglandscape.com/ci/lotilaner-ophthalmic-solution-0-25. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab